To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)

Inclusion Criteria:

• Patients must be of non-childbearing potential and female patients must have anegative pregnancy test at the Screening Visit

• Histologically and/or cytologically confirmed cancer with ECOG ≤2

• Life expectancy of ≥ 3 months

• Assigned to receive the first cycle of a new multi-day chemotherapy regimenincluding the daily administration of cytotoxic agent(s) with the emetogenicpotential of level 3-5 (Hesketh Classification) on 3-5 days

Exclusion Criteria:

• Hypersensitivity to adhesive plasters

• Contraindications to 5-HT3 receptor antagonists

• Clinically relevant abnormal laboratory values or hepatic, renal, infectious,neurological or psychiatric disorders or any other major systemic illness at thediscretion of the Investigator

• Any cause for nausea and vomiting other than CINV

• Clinically relevant abnormal ECG parameters

• Concomitant radiotherapy of total body, brain or upper abdomen within one week ofstudy entry or planned during the study

• A patient taking a medication to control the symptoms of a brain tumour, brainmetastasis or seizure disorder